Natera (NTRA) Insider Rowan Chapman Sells $643K of Stock

Rowan Chapman, associated with Natera, Inc. (NasdaqGS: NTRA), sold 2,964 shares of the company on June 16, 2026. The transaction was valued at $642,535, with an average selling price of $216.78 per share. This was a planned sale under Rule 10b5-1, which allows insiders to set up a trading plan for selling stocks.

Insider Buying and Selling at Natera, Inc.

Rowan Chapman wasn't the only insider selling shares recently. On June 15, 2026, Jonathan Sheena sold 3,150 shares at an average price of $211.14, and Matthew Rabinowitz, the Executive Chairman, sold 50,000 shares at $214.91 on the same day. Earlier, on June 12, Rabinowitz sold another 50,000 shares at $214.03. Meanwhile, Gail Boxer Marcus sold 11,000 shares on June 5 at $217.21 but also bought 11,000 shares on the same day at $22.83.

Other Institutional Activity in Natera, Inc.

Several major institutional investors have also adjusted their positions in Natera. JPMorgan Chase & Co increased its holdings by 532,333 shares, bringing its total to 13,386,667 shares valued at approximately $2.5 billion. Price T Rowe Associates Inc. added 1,312,887 shares, resulting in a total of 12,184,876 shares worth about $2.44 billion. BlackRock, Inc. trimmed its position by 182,103 shares, now holding 10,677,338 shares valued at $2.14 billion. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both reported new positions, with 6,008,496 and 5,644,695 shares, respectively. Wellington Management Group LLP reduced its stake by 207,732 shares, leaving it with 4,768,593 shares valued at $953.67 million.

Natera, Inc. Stock Down 43.2%

Shares of Natera, Inc. are trading near $225.94. The company has a market capitalization of approximately $31.5 billion. Despite not having a meaningful P/E ratio due to losses, it has a beta of 1.544, indicating higher volatility compared to the market. The stock's 52-week range is between $131.81 and $256.36, and it trades with a 50-day moving average of $207.12 and a 200-day moving average of $205.97. Natera maintains a current ratio of 2.96 and a quick ratio of 2.70, with a debt-to-equity ratio of 13.53.

Recent Earnings

Natera reported revenue of $2.5 billion, showing growth of 38.8%. However, the company posted a net margin of -9.05% and a return on equity of -15.02%, reflecting ongoing challenges in profitability. The next earnings report is anticipated on August 6, 2026.

Analysts Set New Price Targets

Analyst activity around Natera has been robust. RBC Capital reinstated coverage on June 12, 2026, with a 'buy' rating and a $275 target. Goldman Sachs initiated coverage with a 'hold' rating and a $245 target on June 5. Wolfe Research assumes coverage with a 'buy' rating and a $260 target on June 2. Overall, the consensus among 20 analysts is a 'buy' recommendation, with a target mean price of $260.05, ranging from a low of $193 to a high of $300.

About Natera, Inc.

Natera, Inc. is a healthcare company based in Austin, Texas, specializing in diagnostics and research. It develops and sells molecular testing services globally, including personalized blood tests for cancer monitoring and prenatal screening. Led by CEO Steven Leonard Chapman, Natera employs over 6,000 people and partners with laboratories and pharmaceutical companies to deliver its products.

Bottom Line

Insider transactions like Rowan Chapman's planned sale offer a glimpse into the internal movements within Natera, Inc. The company's stock is closely watched due to its significant market cap and wide analyst coverage. Investors should note that the 13F filings and insider transactions are historical and may not reflect current positions.